S Li
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann B, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C, Lindtner J, Price K, Castiglione-Gertsch M, Coates A, Gelber R, Li S, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16:716-25.
May 1, 2005Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
May 1, 2005Ann Oncol 2005; 16:716-25
Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann Beat, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C-M, Lindtner J, Price K N, Castiglione-Gertsch M, Coates A S, Gelber R D, Li S, Goldhirsch A
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
Berclaz G, Thürlimann B, Fey M, Mendiola C, Werner I, Simoncini E, Crivellari D, Gelber R, Goldhirsch A, Snyder R, Collins J, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam C, Holmberg S, Lindtner J, Erien D, International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15:875-84.
Jun 1, 2004Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
Jun 1, 2004Ann Oncol 2004; 15:875-84
Berclaz G, Thürlimann Beat, Fey M F, Mendiola C, Werner I Dudley, Simoncini E, Crivellari D, Gelber R D, Goldhirsch A, Snyder R, Collins J, Li S, Price K N, Coates A S, Castiglione-Gertsch M, Rudenstam C-M, Holmberg S B, Lindtner J, Erien D, International Breast Cancer Study Group
Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL
Li S, Gillessen Sommer S, Tomasson M, Dranoff G, Gilliland D, Van Etten R. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 2001; 97:1442-50.
Mar 1, 2001Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL
Mar 1, 2001Blood 2001; 97:1442-50
Li S, Gillessen Sommer Silke, Tomasson M H, Dranoff G, Gilliland D G, Van Etten R A
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
Tomasson M, Williams I, Li S, Kutok J, Cain D, Gillessen Sommer S, Dranoff G, Van Etten R, Gilliland D. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. Blood 2001; 97:1435-41.
Mar 1, 2001Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
Mar 1, 2001Blood 2001; 97:1435-41
Tomasson M H, Williams I R, Li S, Kutok J, Cain D, Gillessen Sommer Silke, Dranoff G, Van Etten R A, Gilliland D G